Valuation: Intellipharmaceutics International Inc.

Market Cap 1.41M 1.26M 1.16M 1.05M 1.97M 134M 2M 13.96M 5.53M 69.95M 5.28M 5.17M 221M P/E 2021
-0.69x
P/E 2022 -0.82x
Enterprise Value 3.65M 3.26M 3.01M 2.73M 5.1M 346M 5.19M 36.22M 14.34M 181M 13.69M 13.4M 572M EV / Sales 2021
-
EV / Sales 2022 70.4x
Free-Float
98.24%
Yield 2021 *
-
Yield 2022 -
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0.15
5 years 0
Extreme 1.0E-6
0.3
10 years 0
Extreme 1.0E-6
33.5
Manager TitleAgeSince
Director of Finance/CFO - -
Comptroller/Controller/Auditor - 2007-03-31
Corporate Officer/Principal - 2014-01-31
Director TitleAgeSince
Director/Board Member - 2004-08-31
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 33
-2.54%+1.31%+55.10%+120.84% 1,135B
-1.42%+3.23%+37.07%+74.26% 636B
+0.16%+0.08%+25.14%+97.36% 505B
-0.31%+3.09%+43.92%+64.55% 378B
-1.34%-0.47%+66.63%+40.56% 358B
-0.68%+2.65%+22.46%+51.48% 295B
-1.20%+3.04%+2.62%+26.97% 266B
-1.79%+1.57%+49.97%+60.87% 237B
-0.73%-0.10%+29.24%+101.19% 193B
Average -0.60%+1.95%+36.91%+70.90% 400.43B
Weighted average by Cap. -0.26%+2.66%+40.99%+82.13%

Financials

2021 2022
Net sales - 65.73K 58.7K 54.22K 49.14K 91.93K 6.24M 93.45K 653K 258K 3.27M 247K 241K 10.31M
Net income -5.15M -4.59M -4.24M -3.85M -7.2M -488M -7.32M -51.08M -20.22M -256M -19.31M -18.9M -807M -2.89M -2.58M -2.39M -2.16M -4.05M -275M -4.11M -28.71M -11.37M -144M -10.85M -10.62M -454M
Net Debt 1.15M 1.02M 945K 856K 1.6M 109M 1.63M 11.37M 4.5M 56.97M 4.3M 4.21M 180M 2.24M 2M 1.85M 1.68M 3.14M 213M 3.19M 22.26M 8.81M 112M 8.41M 8.24M 352M
Logo Intellipharmaceutics International Inc.
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company’s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.
Employees
11
  1. Stock Market
  2. Stocks
  3. IPCIQ Stock